Shanghai Hile Bio-tech (603718) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Shanghai Hile Bio-tech ¥0.92, price ¥3.07, upside -70.0%, quality 65 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Shanghai Hile Bio-tech for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥2.61 – ¥17.34 · fair‑value band ¥0.6800 – ¥1.23 · the ¥3.07 price screens above the ¥0.9200 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Shanghai Hile Bio-tech in your weekly email
Every Wednesday you see whether Shanghai Hile Bio-tech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials.
Show more
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry reagents, latex enhanced immune turbidimetry reagents, enzyme-linked immunosorbent products, and related diagnostic kits, including matrix metalloproteinase 3, IV collagen, adiponectin, creatine kinase isoenzyme, hepatic bile acid, cardiac troponin I, heparin binding protein, hemoglobin A1C, lipoprotein phospholipase A2, heart fatty acid binding protein, ferritin, sialoglycoside antigen, and procalcitonin kits. The Oral Tissue Repair and Regeneration Materials segment provides oral bone repair materials, implant systems, natural bone repair materials, oral restorative films, collagen-based bone repair matrices, and soft tissue repair matrices, primarily for dental implantation and maxillofacial bone defect repair. The company was founded in 1981 and is headquartered in Shanghai, China.
Stock analysis
Shanghai Hile Bio-tech (603718) currently trades at ¥3.07, while our model-based Fair Value estimate is ¥0.9200, implying the stock looks roughly 233.7% overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of ¥1.40 per share, and 0 of the 15 models we run sit above the ¥3.07 price.
Bear case: the Earnings-Based group reads lowest at ¥0.4200, and 15 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥0.6800 (bear) to ¥1.23 (bull), the price of ¥3.07 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Shanghai Hile Bio-tech reported revenue of 188M CNY in FY2025 versus 347M CNY in FY2021, a compound −14.2%/yr. Reported net income was −311M CNY in FY2025.
Key figures
Market cap 2.0B CNY (≈ $300M) · P/S ratio 11.2 · EPS (TTM) ¥−0.4900 · Dividend yield 6.3% · Net margin −182% · Return on equity −22.7% · Return on assets (EBIT) 5.0% · Operating margin 20.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 57% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −70%, 603718 screens richer than that median.
Fair Value models
Bear ¥0.6800Fair Value ¥0.9200Bull ¥1.23
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.23/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−30.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.2%
Start year 2020 (pandemic). Over 10 years: −5.1% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8.3% (2020) → 25.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +23.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score65 · Top 25%
Fair Value upside−70% · Below median
Profitability
Return on assets1% · Above median
Net margin (TTM)−182% · Bottom 25%
Operating margin (TTM)21% · Top 25%
Growth and dividend
Revenue growth−23% · Bottom 25%
Dividend yield (TTM)6.3% · Top 25%
Balance sheet
Debt / equity0.15× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.34× · Cheapest 25%
P/S (TTM)1.73× · Cheaper than median
P/FCF6.4× · Pricier than median
EV/EBITDA4.9× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)93· sector 97
DIVIDEND (yield)100· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Shanghai Hile Bio-tech (603718) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥0.9200 versus a price of ¥3.07, about −70% upside (overvalued).
What is the fair value of 603718?
Our model-based fair value for Shanghai Hile Bio-tech is ¥0.9200 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥3.07.
What is the quality score of 603718?
Shanghai Hile Bio-tech has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Hile Bio-tech (603718)?
Our model-based price target is the fair value of ¥0.9200 (as of Sep 24, 2026) from 15 valuation models. Cautious scenario ¥0.6800, optimistic scenario ¥1.23. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Hile Bio-tech stock forecast for 2026?
Our models put fair value at ¥0.9200, about −70% upside versus a price of ¥3.07 (overvalued). Cautious scenario ¥0.6800, optimistic scenario ¥1.23. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Hile Bio-tech (603718)?
Shanghai Hile Bio-tech reported trailing-twelve-month revenue of about 173M CNY (latest available figure, as of Sep 24, 2026).
Does Shanghai Hile Bio-tech pay a dividend?
Shanghai Hile Bio-tech currently shows a dividend yield of about 6.31% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Shanghai Hile Bio-tech (603718)?
For today's price to be fair in a discounted-cash-flow model, Shanghai Hile Bio-tech would have to grow free cash flow by +25.9 % per year for five years (discount rate 11.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -6.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 603718 use?
Our models discount Shanghai Hile Bio-tech at 11.9 %: a base by market capitalisation (micro), damped by beta 0.20, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shanghai Hile Bio-tech that is +25.9 % per year a year over ten years, using the same discount rate (11.9 %) and the same formula as our fair value.
How much growth has Shanghai Hile Bio-tech (603718) delivered so far?
Over the past 5 years revenue at Shanghai Hile Bio-tech grew -6.2 % a year. The price currently implies +25.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shanghai Hile Bio-tech (603718) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Shanghai Hile Bio-tech (+25.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shanghai Hile Bio-tech (603718)?
The free-cash-flow yield on the price is 2.32 %: that much free cash flow Shanghai Hile Bio-tech produces per unit of market value. When it exceeds the discount rate of our models (11.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shanghai Hile Bio-tech (603718)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Hile Bio-tech it is ¥0.9200 per share (as of Sep 24, 2026), against a price of ¥3.07. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Shanghai Hile Bio-tech stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 603718 trades above its calculated fair value: price ¥3.07, fair value ¥0.9200, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 603718?
No. The price is what the market pays today (¥3.07); the fair value is what the company's own numbers justify (¥0.9200). For Shanghai Hile Bio-tech the two are ¥2.15 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Hile Bio-tech worth?
The market values Shanghai Hile Bio-tech at about 2.0B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥3.07; our models calculate a fair value of ¥0.9200 per share.
What do the bullish and bearish scenarios say about 603718?
Our models span a range for Shanghai Hile Bio-tech: cautious scenario ¥0.6800, base ¥0.9200, optimistic ¥1.23 per share (as of Sep 24, 2026, price ¥3.07). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Shanghai Hile Bio-tech (603718)?
Balance-sheet figures for Shanghai Hile Bio-tech (as of Sep 24, 2026): return on equity −22.7%, debt of 0.15 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is 603718 from its 52-week high?
Shanghai Hile Bio-tech trades at ¥3.07, about 57% below its 52-week high of ¥7.20 and 18% above the low of ¥2.61 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.9200 is for.
Which stocks are comparable to Shanghai Hile Bio-tech?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Hile Bio-tech stock attractive at the current price?
The data as of Sep 24, 2026: price ¥3.07, calculated fair value ¥0.9200 (−70%), Quality Score 65/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 603718 calculated?
We run Shanghai Hile Bio-tech through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥0.9200, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Shanghai Hile Bio-tech itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Hile Bio-tech (603718)?
The closing price on Sep 24, 2026 was ¥3.07. Our model-based fair value is ¥0.9200, about −70% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Hile Bio-tech right now?
The price sits above even our optimistic bull case (¥1.23). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥0.6800 to ¥1.23) leaves room in how you read the outcome.
Where does the earnings growth of Shanghai Hile Bio-tech (603718) come from?
Earnings per share at Shanghai Hile Bio-tech grew −1.2 % a year from 2013 to 2024. Broken into its drivers: revenue per share −3.9 %, EBIT margin −0.2 %, tax rate +0.2 %, residual (interest, one-offs) +2.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Shanghai Hile Bio-tech
How large is the market capitalisation of Shanghai Hile Bio-tech (603718)?
The market capitalisation of Shanghai Hile Bio-tech is 2.0B CNY (≈ $300M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Hile Bio-tech (603718)?
The price-to-sales ratio of Shanghai Hile Bio-tech is 11.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Hile Bio-tech (603718)?
Earnings per share at Shanghai Hile Bio-tech are ¥−0.4900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shanghai Hile Bio-tech (603718)?
The dividend yield of Shanghai Hile Bio-tech is 6.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shanghai Hile Bio-tech (603718)?
The net margin of Shanghai Hile Bio-tech is −182% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Hile Bio-tech (603718)?
The return on equity (ROE) of Shanghai Hile Bio-tech is −22.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Hile Bio-tech (603718)?
On an EBIT basis the return on assets of Shanghai Hile Bio-tech is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Hile Bio-tech (603718)?
The operating margin of Shanghai Hile Bio-tech is 20.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Hile Bio-tech (603718)?
Revenue at Shanghai Hile Bio-tech is growing −23.3% versus a year earlier (3y avg −14.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai Hile Bio-tech (603718)?
Earnings per share at Shanghai Hile Bio-tech are growing −50.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Shanghai Hile Bio-tech (603718) hold?
Shanghai Hile Bio-tech holds more cash than debt, 309M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Shanghai Hile Bio-tech in the live analysis
One click puts Shanghai Hile Bio-tech on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
